Drugs / Tetanus-diphtheria (Td) toxoid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03688178 | Aug 2020 → Mar 2027 expected | glioblastoma | Annick Desjardins, MD | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetanus-diphtheria (Td) toxoid | “Tetanus-diphtheria (Td) toxoid” NCT03688178 ↗ |
| Known as | Td | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03688178 ↗ |
| Modality | Vaccine | “Tetanus-diphtheria (Td) toxoid is used for active immunization in children and adults” NCT03688178 ↗ |
| Route | Other | “administered to a single side of the groin given intradermally” NCT03688178 ↗ |